References on the Administration of Agents to Immunodeficient Mice Using ALZET® Osmotic Pumps

Q3338 Gmeiner,W.H., Lema-Tome,C., Gibo,D., Jennings-Gee,J., Milligan,C., Debinski,W. Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. Journal of Neuro-oncology 2014; 116(-3-):447-454. >>> F10; PBS; CSF/CNS (thalamus); Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; animal info (nu/nu, 7 weeks old); ALZET brain infusion kit 3 used; cancer (human glioblastoma G48a); dose-response (pg.451-452, fig.3b and fig.4); no stress (see pg. 451); tissue perfusion (posterior thalamus); immunology; “F10 does not penetrate the BBB in healthy mice (data not shown), thus intra-cranial (i.c.) administration of F10 results in high local concentrations that may be therapeutically beneficial. Dose-finding studies in nude mice demonstrate that F10 administered i.c. using an Alzet osmotic mini-pump at doses up to 200 mg/kg administered over 7 days are well-tolerated and do not cause damage to normal brain (Fig. 2b).” pg 451; Pumps primed in 37C saline overnight; F10 is a novel antitumor agent;.

Q3328 Biddlestone-Thorpe,L., Sajjad,M., Rosenberg,E., Beckta,J.M., Valerie,N.C.K., Tokarz,M., Adams,B.R., Wagner,A.F., Khalil,A., Gilfor,D., Golding,S.E., Deb,S., Temesi,D.G., Lau,A., O’Connor,M.J., Choe,K.S., Parada,L.F., Lim,S.K., Mukhopadhyay,N.D., Valerie,K. ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation. Clinical Cancer Research 2013; 19(-12-):3189-3200. >>> KU-60019; PBS; CSF/CNS; Mice (nude); 1007D; 1002; 2002; 7 days; 19 days; Controls received mp w/ vehicle; animal info (female, nude, athymic, 15-20g, 5-6 weeks old); ALZET brain infusion kit 3 used; cancer (glioma); tissue perfusion (glioma); “To reach meaningful drug concentrations of KU-60019 within the tumor, the BBB/BTB need to be bypassed or drugs administered locally. Both osmotic pumps, as well as clinically used CED, partially bypass the BBB/BTB and deliver drugs directly to the tumor to improve efficacy and reduce potential systemic toxicity” pg3194; KU-60019 is a kinase inhibitor.

Q2692 Ciceroni,C., Bonelli,M., Mastrantoni,E., Niccolini,C., Laurenza,M., Larocca,L.M., Pallini,R., Traficante,A., Spinsanti,P., Ricci-Vitiani,L., Arcella,A., De Maria,R., Nicoletti,F., Battaglia,G., Melchiorri,D. Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. CELL DEATH AND DIFFERENTIATION 2013; 20(-3-):396-407. >>> LY341495; Saline; IP; Mice (nude); 28 days; Control animals received mp w/ vehicle; animal info (male, CD1, 20-22 g).

Q2557 Gopinath,S., Malla,R., Alapati,K., Gorantla,B., Gujrati,M., Dinh,D.H., Rao,J.S. Cathepsin B and uPAR regulate self-renewal of glioma-initiating cells through GLI-regulated Sox2 and Bmi1 expression. Carcinogenesis 2013; 34(-3-):550-559. >>> Plasmid, pCU; plasmid, SV; CSF/CNS (intratumoral); Mice (nude); ; Control animals received mp w/ PBS; animal info (5 wks old, female, nude); infusion rate of 0.25 ul/hr; pCU plasmid is a bicistronic shRNA construct directed against both uPAR and cathepsin B; cancer (glioblastoma).

Q3092 Kaneko,N., Yamanaka,K., Kita,A., Tabata,K., Akabane,T., Mori,M. Synergistic Antitumor Activities of Sepantronium Bromide (YM155), a Survivin Suppressant, in Combination with Microtubule-Targeting Agents in Triple-Negative Breast Cancer Cells. BIOLOGICAL&PHARMACEUTICAL BULLETIN 2013; 36(-12-):1921-1927. >>> YM155; Saline; SC; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; animal info (female); cancer (breast); immunology; YM155 aka sepantronium bromide; Pumps used in conjunction with docetaxel IV bolus injections (20 mg/kg).

Q2613 Katz,S.C., Burga,R.A., Naheed,S., Licata,L.A., Thorn,M., Osgood,D., Nguyen,C.T., Espat,N.J., Fletcher,J.A., Junghans,R.P. Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor. Journal of Translational Medicine 2013; 11(-;-):U1-U10. >>> Interleukin-2, human; SC; Mice (nude); ; Animal info (6 wks old, male, Nu/J); 7-day pumps used.

Q2986 Kesanakurti,D., Chetty,C., Maddirela,D.R., Gujrati,M., Rao,J.S. Essential role of cooperative NF-kappaB and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma. ONCOGENE 2013; 32(-43-):5144-5155. >>> Oligonucleotide, antisense; plasmid, scrambled vector, pSV; PBS; SC; Mice (nude); 2004; ; Cancer (glioblastoma); animal info (nu/nu mice).

Q2638 Kesanakurti,D., Chetty,C., Dinh,D.H., Gujrati,M., Rao,J.S. Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with alpha5beta1 integrin in glioma. ONCOGENE 2013; 32(-3-):327-340. >>> Plasmid, scrambled vector; RNA, small interfering; Mice (nude); 2004; ; Animal info (nu/nu, 4-6 wks old, athymic); MMP-2 siRNA.

Q2574 Kogame,A., Tagawa,Y., Shibata,S., Tojo,H., Miyamoto,M., Tohyama,K., Kondo,T., Prakash,S., Shyu,W.C., Asahi,S. Pharmacokinetic and Pharmacodynamic Modeling of Hedgehog Inhibitor TAK-441 for the Inhibition of Gli1 messenger RNA Expression and Antitumor Efficacy in Xenografted Tumor Model Mice. Drug Metabolism and Disposition 2013; 41(-4-):727-734. >>> TAK-441; DMSO; PEG; SC; Mice (nude); 1003D; 3 days; Animal info (female, athymic, nu/nu, Balb/c, 8 wks old, 18-26 g); TAK-441 is a potent, selective hedgehog signaling pathway inhibitor; cancer; pk study.

Q2875 Lin,Q., Wang,F.F., Yang,R., Zheng,X.M., Gao,H.B., Zhang,P. Effect of Chronic Restraint Stress on Human Colorectal Carcinoma Growth in Mice. PLoS One 2013; 8(-4-):U1127-U1137. >>> Epinephrine; atenolol; ICI 118,551; PBS; ascorbic acid; SC; Mice (nude); 1002; 2 weeks; Controls received mp w PBS, PHE (2mg/kg/d) and PRO (2mg/kg/d), CRS PBS, CRS PHE (2mg/kg/d) and PRO (2mg/kg/d); animal info (nude); cancer (colorectal); dose-response (Fig.4, S5); used microosmotic pumps to reduce stress associated w animal handling, and bypass the effect of quick metabolism that is associated with stress hormones and antagonists; ICI 118,551 is a specific B2-AR antagonist;.

Q2564 Mo,W., Chen,J., Patel,A., Zhang,L., Chau,V., Li,Y.J., Cho,W., Lim,K., Xu,J., Lazar,A.J., Creighton,C.J., Bolshakov,S., McKay,R.M., Lev,D., Le,L.Q., Parada,L.F. CXCR4/CXCL12 Mediate Autocrine Cell-Cycle Progression in NF1-Associated Malignant Peripheral Nerve Sheath Tumors. Cell 2013; 152(-5-):1077-1090. >>> AMD 3100; SC; Mice (nude); 2 months; Control animals received mp w/ saline; animal info (nu/nu, athymic, female, 16 wks old); long-term study.

Q2847 Sohn,Y.B., Lee,J., Cho,S.Y., Kim,S.J., Ko,A.R., Nam,M.H., Jin,D.K. Improvement of CNS Defects Via Continuous Intrathecal Enzyme Replacement by Osmotic Pump in Mucopolysaccharidosis Type II Mice. AMERICAN JOURNAL OF MEDICAL GENETICS PART A 2013; 161A(-5-):1036-1043. >>> Iduronate-2-sulfatase; , recomb. human; CSF, artificial; CSF/CNS (intrathecal); Mice (nude); 2004; 3 weeks; Control animals received mp w/ vehicle; animal info (KDS KO, wt, male, female); good methods (pg 1037) “The catheter and osmotic mini-pump were sewed to the muscle to fix the devices, and the opened skin was sewn closed”; ALZET intrathecal catheter used.

Q3271 Zhuang,T., Chelluboina,B., Ponnala,S., Velpula,K.K., Rehman,A.A., Chetty,C., Zakharian,E., Rao,J.S., Veeravalli,K.K. Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration. BMC CANCER 2013; 13(-;-):U1-U11. >>> Plasmid, MMP-9; plasmid, uPAR; plasmid, MMP-9-uPAR; Medium, serum free; CSF/CNS; Mice (nude); 5 weeks; Animal info (nude); cancer (glioma);.

Q2296 Broadhead,M.L., Choong,P.F.M., Dass,C.R. Efficacy of Continuously Administered PEDF-Derived Synthetic Peptides against Osteosarcoma Growth and Metastasis. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY 2012; ;(-;-):U1-U10. >>> StVOrth-2; StVOrth-3; Water, sterile; IP; Mice (nude); 1002; ; Control animals received mp w/ vehicle; animal info (BALB/c, 5 wks old); peptides; “It is known that the pumps are capable of delivering a steady state quantity of peptides into the abdominal cavity [18, 19], which will eventually be taken into the microvasculature supplying the abdominal region.” pg 3; cancer (osteosarcoma).

Q1856 Cook,C.C., Kim,A., Terao,S., Gotoh,A., Higuchi,M. Consumption of oxygen: a mitochondrial-generated progression signal of advanced cancer. Cell Death&Disease 2012; 3(-;-):U115-U126. >>> Mevalonate; SC; Mice (nude); 2004; ; Controls received mp w/ saline; animal info (athymic, BALB/c, nu/nu, 4 wks old).

Q2063 Dubrovska,A., Hartung,A., Bouchez,L.C., Walker,J.R., Reddy,V.A., Cho,C.Y., Schultz,P.G. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. British Journal of Cancer 2012; 107(-1-):43-52. >>> AMD 3100; SC; Mice (nude); ; Controls received mp w/ saline; animal info (athymic, nu/nu, 5-6 wks old, ovariectomized); cancer (breast).

Q2074 Ghadimi,M.P., Young,E.D., Belousov,R., Zhang,Y.Q., Lopez,G., Lusby,K., Kivlin,C., Demicco,E.G., Creighton,C.J., Lazar,A.J., Pollock,R.E., Lev,D. Survivin Is a Viable Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors. Clinical Cancer Research 2012; 18(-9-):2545-2557. >>> YM155; Saline; SC; Mice (nude/SCID); 1003D; 3 days; Controls received mp w/ vehicle; animal info (SCID, STS26T).

Q1776 Gibon,E., Ma,T., Ren,P.G., Fritton,K., Biswal,S., Yao,Z.Y., Smith,L., Goodman,S.B. Selective inhibition of the MCP-1-CCR2 ligand-receptor axis decreases systemic trafficking of macrophages in the presence of UHMWPE particles. Journal of Orthopaedic Research 2012; 30(-4-):547-553. >>> Polyethylene particles, UHMWPE; Ethanol; PBS; Bone (femur); Mice (nude); 2006; ; Animal info (8-9 wks old, nu/nu); bioluminescence.

Q1992 Gil,G.A., Silvestre,D.C., Tomasini,N., Bussolino,D.F., Caputto,B.L. Controlling Cytoplasmic c-Fos Controls Tumor Growth in the Peripheral and Central Nervous System. Neurochemical Research 2012; 37(-6-):1364-1371. >>> Oligonucleotide, antisense; oligonucleotide, scrambled; CSF/CNS (caduate putamen); Mice (nude); 28 days; Controls received mp w/ vehicle; animal info (nu/nu, 4-6 wks old); antisense (c-Fos); cancer (glioblastoma).

Q2565 Gogineni,V.R., Gupta,R., Nalla,A.K., Velpula,K.K., Rao,J.S. uPAR and cathepsin B shRNA impedes TGF-beta1-driven proliferation and invasion of meningioma cells in a XIAP-dependent pathway. Cell Death&Disease 2012; 3(-;-):U20-U29. >>> Plasmid, scrambled vector, pSV; plasmid, pUC; Mice (nude); ; Control animals received mp w/ scrambled vector; animal info (nu/nu, athymic); pUC is a bicistronic shRNA constructs targeting uPAR and cathepsin B.

Q2350 Heger,N.E., Hall,S.J., Sandrof,M.A., McDonnell,E.V., Hensley,J.B., McDowel,E.N., Martin,K.A., Gaido,K.W., Johnson,K.J., Boekelheide,K. Human Fetal Testis Xenografts Are Resistant to Phthalate-Induced Endocrine Disruption. Environmental Health Perspectives 2012; 120(-8-):1137-1143. >>> Cytidine, bromodeoxy; SC; Mice (nude); rat (nude); 2001; ; Wound clips used.

Q2323 Kaneko,M.K., Kunita,A., Abe,S., Tsujimoto,Y., Fukayama,M., Goto,K., Sawa,Y., Nishioka,Y., Kato,Y. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. CANCER SCIENCE 2012; 103(-11-):1913-1919. >>> NZ-1; immunoglobulin G, rat; IP; Mice (nude); 2002; ; Animal info (BALB/c); NZ-1 is a rat antipodoplanin monoclonal antibody.

Q2563 Kesanakurti,D., Chetty,C., Maddirela,D.R., Gujrati,M., Rao,J.S. Functional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in glioma. Cell Death&Disease 2012; 3(-;-):U78-U90. >>> Plasmid, scrambled vector; plasmid, PAK4si; Mice (nude); 2004; ; Animal info (female, nu/nu).

Q2313 Kim,H.S., Masko,E.M., Poulton,S.L., Kennedy,K.M., Pizzo,S.V., Dewhirst,M.W., Freedland,S.J. Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU INTERNATIONAL 2012; 110(-7-):1062-1069. >>> Cyano-4-hydroxycinnamate, alpha; DMSO; PEG; SC; Mice (nude); 42 days; Control animals received mp w/ vehicle; animal info (athymic, male, 6-8 wks old); cancer (prostate); 9 mm wound clips used; post op. care (triple antibiotic ointment).

Q1975 Kotipatruni,R.R., Nalla,A.K., Asuthkar,S., Gondi,C.S., Dinh,D.H., Rao,J.S. Apoptosis Induced by Knockdown of uPAR and MMP-9 is Mediated by Inactivation of EGFR/STAT3 Signaling in Medulloblastoma. PLoS One 2012; 7(-9-):U893-U905. >>> RNA, small hairpin; CSF/CNS (intratumoral); Mice (nude); 2001; ; Animal info (nude); tissue perfusion (tumor); cancer.

Q1859 Ligumsky,H., Wolf,I., Israeli,S., Haimsohn,M., Ferber,S., Karasik,A., Kaufman,B., Rubinek,T. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Research and Treatment 2012; 132(-2-):449-461. >>> Exendin-4; PBS; SC; Mice (nude); 4 weeks; Controls received mp w/ vehicle; animal info (female, athymic, 6 wks old); cancer (breast); 4-week pump used.

Q1926 Malla,R.R., Gopinath,S., Gondi,C.S., Alapati,K., Dinh,D.H., Tsung,A.J., Rao,J.S. uPAR and cathepsin B downregulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma. Journal of Neuro-oncology 2012; 107(-1-):69-80. >>> Plasmid, MMP-9/cathepsin B; CSF/CNS; Mice (nude); ; Controls received mp w/ scrambled vector plasmid or PBS; pump infusion rate of 0.25 ul/hr; cancer (glioma).

Q2013 Na,Y.S., Yang,S.J., Kim,S.M., Jung,K.A., Moon,J.H., Shin,J.S., Yoon,D.H., Hong,Y.S., Ryu,M.H., Lee,J.L., Lee,J.S., Kim,T.W. YM155 Induces EGFR Suppression in Pancreatic Cancer Cells. PLoS One 2012; 7(-6-):U422-U431. >>> YM155; SC; Mice (nude); 1003D; 2 weeks; Controls received mp w/ vehicle; animal info (athymic, nu/nu, 5 wks old, female); cancer (pancreatic).

Q1797 Okamoto,K., Okamoto,I., Hatashita,E., Kuwata,K., Yamaguchi,H., Kita,A., Yamanaka,K., Ono,M., Nakagawa,K. Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting Survivin. MOLECULAR CANCER THERAPEUTICS 2012; 11(-1-):204-213. >>> YM155; Mice (nude); 1003D; 7 days; Animal info (5-6 wks old, female, athymic, nu/nu, BALB/c); cancer.

Q1924 Veeravalli,K.K., Ponnala,S., Chetty,C., Tsung,A.J., Gujrati,M., Rao,J.S. Integrin alpha-9-beta1-mediated cell migration in glioblastoma via SSAT and Kir4.2 potassium channel pathway. Cellular Signalling 2012; 24(-1-):272-281. >>> Plasmid, MMP-9/uPAR; plasmid, MMP-9/cathepsin B; CSF/CNS; Mice (nude); ; Pump infusion rate of 0.2 ul/hr; MMP-9/uPAR plasmid also known as MU-sh; MMP-9/cathepsin B plasmid also known as MC-sh; cancer (glioma).

Q2255 Yoon,D.H., Shin,J.S., Jin,D.H., Hong,S.W., Jung,K.A., Kim,S.M., Hong,Y.S., Kim,K.P., Lee,J.L., Suh,C., Lee,J.S., Kim,T.W. The Survivin Suppressant YM155 Potentiates Chemosensitivity to Gemcitabine in the Human Pancreatic Cancer Cell Line MiaPaCa-2. Anticancer Research 2012; 32(-5-):1681-1688. >>> YM155; Mice (nude); 1003D; 3 days; Animal info (5 wks old, female, BALB/c, nu/nu); infusion for 3-days a week for two weeks; cancer (pancreatic).

Q1796 Zou,H.Y., Li,Q.H., Lee,J.H., Arango,M.E., Burgess,K., Qiu,M., Engstrom,L.D., Yamazaki,S., Parker,M., Timofeevski,S., Cui,J.J., McTigue,M., Los,G., Bender,S.L., Smeal,T., Christensen,J.G. Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor. MOLECULAR CANCER THERAPEUTICS 2012; 11(-4-):1036-1047. >>> PF-04217903; SC; Mice (nude); 14 days; Controls received mp w/ vehicle; animal info (female, athymic, nu/nu); cancer; dose response (Fig 2C); enzyme inhibitor (c-Met kinase).

Q2212 Aljuffali,I.A., Mock,J.N., Costyn,L.J., Nguyen,H., Nagy,T., Cummings,B.S., Arnold,R.D. Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer. CANCER BIOLOGY&THERAPY 2011; 12(-5-):407-420. >>> Topotecan; Saline; SC; Mice (nude); 28 days; Controls received mp w/ vehicle; animal info (NCr, male); cancer (prostate).

Q0966 Asuthkar,S., Nalla,A.K., Gondi,C.S., Dinh,D.H., Gujrati,M., Mohanam,S., Rao,J.S. Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9 – mediated EMT. NEURO-ONCOLOGY 2011; 13(-10-):1059-1073. >>> Plasmid, MMP-9; CSF/CNS; Mice (nude); 2001; 1 week; Controls received mp w/ scrambled vector; animal info (nude).

Q1661 Atkinson,J.M., Shelat,A.A., Carcaboso,A.M., Kranenburg,T.A., Arnold,L.A., Boulos,N., Wright,K., Johnson,R.A., Poppleton,H., Mohankumar,K.M., Feau,C., Phoenix,T., Gibson,P., Zhu,L.Q., Tong,Y.A., Eden,C., Ellison,D.W., Priebe,W., Koul,D., Yung,W.K.A., Gajjar,A., Stewart,C.F., Guy,R.K., Gilbertson,R.J. An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma. CANCER CELL 2011; 20(-3-):384-399. >>> Fluorouracil, 5-; SC; Mice (nude); 2001D; ; Animal info (CD-1, 8 wks old, 23-28 g); cancer.

Q1024 Daigle,S.R., Olhava,E.J., Therkelsen,C.A., Majer,C.R., Sneeringer,C.J., Song,J., Johnston,L.D., Scott,M.P., Smith,J.J., Xiao,Y.H., Jin,L., Kuntz,K.W., Chesworth,R., Moyer,M.P., Bernt,K.M., Tseng,J.C., Kung,A.L., Armstrong,S.A., Copeland,R.A., Richon,V.M., Pollock,R.M. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor. CANCER CELL 2011; 20(-1-):53-65. >>> EPZ004777; Ethanol; water; PEG 300; SC; Mice (nude); 2001; 6, 14 days; Controls received no pump implant; animal info (wks old, nu/nu, female, C57BL/6, 8 wks old); cancer (mixed lineage leukemia); enzyme inhibitor (histone methyltransferase, DOT1L); 10% ethanol used; 50% PEG300 used; pumps replaced after 1 week; “Osmotic pumps were replaced after one week. Irritation caused by compound precipitation was observed in the 100 and 150 mg/ml dose groups, precluding additional pump replacements.” pg 63; “Despite the limited 14 day duration of EPZ004777 exposure achieved, we observed a dose-dependent and statistically significant increase in median survival” pg 58; EPZ004777 is a selective inhibitor of DOT1L.

Q0801 Fujisawa,T., Nakashima,H., Nakajima,A., Joshi,B.H., Puri,R.K. Targeting IL-13Ralpha2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. International Journal of Cancer 2011; 128(-5-):1221-1231. >>> Interleukin-13-Pseudomonas exotoxin, recomb.; IP; Mice (nude); 14 days; Animal info (nu/nu, 5-6 wks old); comparison of IP injections vs IP mp; IL-13-PE is a recombinant immunotoxin; “Mice receiving continuous IL-13-PE exhibited better tumor response compared to bolus administration” pg 1224.

Q2224 Gopinath,S., Alapati,K., Malla,R.R., Gondi,C.S., Mohanam,S., Dinh,D.H., Rao,J.S. Mechanism of p27 upregulation induced by downregulation of cathepsin B and uPAR in glioma. Molecular Oncology 2011; 5(-5-):426-437. >>> Plasmid, uPAR/cathepsin B; plasmid, scrambled vector; IP; Mice (nude); 5 weeks; Controls received mp w/ PBS; cancer (glioma).

Q1108 Gupta,R., Nalla,A.K., Gogineni,V.R., Chetty,C., Bhoopathi,P., Klopfenstein,J.D., Tsung,A.J., Mohanam,S., Rao,J.S. uPAR/Cathepsin B Overexpression Reverse Angiogenesis by Rescuing FAK Phosphorylation in uPAR/Cathepsin B Down Regulated Meningioma. PLoS One 2011; 6(-2-):U298-U308. >>> Plasmid, pCU, pU2, FluPAR/Cathepsin B; Mice (nude); ; Controls received mp w/ control plasmid pSV; animal info (athymic, nu/nu, female, 5-7 wks old); cancer (meningioma).

Q2226 Hwang,Y., Chumbalkar,V., Latha,K., Bogler,O. Forced Dimerization Increases the Activity of Delta EGFR/EGFRvIII and Enhances Its Oncogenicity. MOLECULAR CANCER RESEARCH 2011; 9(-9-):1199-1208. >>> AP20187; Mice (nude); 2 weeks; Controls received mp w/ vehicle; cancer (glioma, glioblastoma).

Q1161 Kesanakurti,D., Chetty,C., Bhoopathi,P., Lakka,S.S., Gorantla,B., Tsung,A.J., Rao,J.S. Suppression of MMP-2 Attenuates TNF-alpha Induced NF-kappa B Activation and Leads to JNK Mediated Cell Death in Glioma. PLoS One 2011; 6(-5-):U239-U252. >>> RNA, small interfering, MMP-2; CSF/CNS (intratumorally); Mice (nude); 2004; ; Animal info (athymic, female, nu/nu, 4-6 wks old); cancer (glioma); tissue perfusion (intratumorally); MMP2 siRNA.

Q1166 Kim,J., Koyanagi,T., Mochly-Rosen,D. PKC delta Activation Mediates Angiogenesis via NADPH Oxidase Activity in PC-3 Prostate Cancer Cells. PROSTATE 2011; 71(-9-):946-954. >>> V1-1, delta; RACK, delta omega; Saline; Mice (nude); 2001; 4 weeks; Controls received mp w/ TAT carrier peptide; animal info (6 wks old, male, nu/nu); peptides; pumps replaced after 2 weeks; cancer (prostate); half-life, 2 weeks in the pump (p. 947); deltaV1-1 is a PKC delta-selective inhibitor; delta gamma RACK is a PKC delta selective activator.

Q1171 Kita,A., Nakahara,T., Yamanaka,K., Nakano,K., Nakata,M., Mori,M., Kaneko,N., Koutoku,H., Izumisawa,N., Sasamata,M. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. LEUKEMIA RESEARCH 2011; 35(-6-):787-792. >>> YM155; SC; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; animal info (BALB/c, nu/nu, male, 5 wks old); cancer (lymphoma).

Q0709 Kurio,N., Shimo,T., Fukazawa,T., Takaoka,M., Okui,T., Hassan,N.M.M., Honami,T., Hatakeyama,S., Ikeda,M., Naomoto,Y., Sasaki,A. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAX and IGF-IR in vitro and in vivo. Experimental Cell Research 2011; 317(-8-):1134-1146. >>> Parathyroid hormone-related peptide (1-34); Saline, physiological; cysteine, L-; SC; Mice (nude); 1007D; ; Controls received mp w/ vehicle; animal info (5 wls old, male, BALB/c); cancer; peptides.

Q1457 Li,J.Y., Su,C.H., Wu,Y.J., Tien,T.Y., Hsieh,C.L., Chen,C.H., Tseng,Y.M., Shi,G.Y., Wu,H.L., Tsai,C.H., Lin,F.Y., Yeh,H.I. Therapeutic Angiogenesis of Human Early Endothelial Progenitor Cells Is Enhanced by Thrombomodulin. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 2011; 31(-11-):2518-U403. >>> TMD23; IV; Mice (nude); 2ML4; ; Controls received mp w/ PBS; animal info (BALB/c, female, athymic, nude, 18-22 g, 8 wks old); incorrectly listed Model 2ML4 for use in mice; TMD23 also known as thrombomodulin domains 2 and 3.

Q1744 Liu,J.Q., Liao,S., Huang,Y.H., Samuel,R., Shi,T., Naxerova,K., Huang,P.G., Kamoun,W., Jain,R.K., Fukumura,D., Xu,L. PDGF-D Improves Drug Delivery and Efficacy via Vascular Normalization, But Promotes Lymphatic Metastasis by Activating CXCR4 in Breast Cancer. Clinical Cancer Research 2011; 17(-11-):3638-3648. >>> AMD 3100; SC; Mice (nude); 14 days; Controls received mp w/ saline; animal info (8-12 wks old, female); 14-day pump used.

Q1722 Malla,R.R., Gopinath,S., Gondi,C.S., Alapati,K., Dinh,D.H., Gujrati,M., Rao,J.S. Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Therapy 2011; 18(-6-):419-434. >>> Cathepsin B; vector, scrambled; Mice (nude); 1002; ; Animal info (athymic, nu/nu, 5-7 wks old).

Q1219 Martiniova,L., Lu,J., Chiang,J., Bernardo,M., Lonser,R., Zhuang,Z.P., Pacak,K. Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy. PLoS One 2011; 6(-2-):U67-U74. >>> LB1; PBS; IP; Mice (nude); 1002; 2 weeks; Controls received mp w/ vehicle; animal info (female, athymic, NCr-nu, 6-10 wks old); cancer; enzyme inhibitor (serine/threonine protein phosphatase 2A, PP2A); chemotherapeutic.

Q1640 Nalla,A.K., Gogineni,V.R., Gupta,R., Dinh,D.H., Rao,J.S. Suppression of uPA and uPAR blocks radiation-induced MCP-1 mediated recruitment of endothelial cells in meningioma. Cellular Signalling 2011; 23(-8-):1299-1310. >>> Plasmid, scrambled vector; plasmid, bi-cistronic, RNA, small interfering; Mice (nude); 2001; ; Animal info (4-6 wks old).

Q1925 Ponnala,S., Veeravalli,K.K., Chetty,C., Dinh,D.H., Rao,J.S. Regulation of DNA Repair Mechanism in Human Glioma Xenograft Cells both In Vitro and In Vivo in Nude Mice. PLoS One 2011; 6(-10-):U374-U386. >>> Plasmid, MMP-9; CSF/CNS; Mice (nude); ; Pump infusion rate of 0.2 ul/hr; cancer (glioma).

Q1958 Raghu,H., Gondi,C.S., Dinh,D.H., Gujrati,M., Rao,J.S. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor. Molecular Cancer 2011; 10(-;-):U1-U15. >>> Plasmid, puPA; plasmid, upAR; plasmid, pU2; plasmid, vector; PBS; CSF/CNS; Mice (nude); ; Cancer (glioblastoma).

Q0705 Ren,P.G., Irani,A., Huang,Z.N., Ma,T., Biswal,S., Goodman,S.B. Continuous Infusion of UHMWPE Particles Induces Increased Bone Macrophages and Osteolysis. Clinical Orthopaedics and Related Research 2011; 469(-1-):113-122. >>> Polyethylene particles, UHMWPE; Saline; Bone (femur); Mice (nude); 2006; 3 weeks; Controls received mp w/ vehicle; animal info (12 wks old, male); post op. care (buprenorphine), pg 115; Fig 1A, diagram of pump and catheter placement; pump connected to titanium rod; bioluminescence; Ultra High Molecular Weight Polyethylene (UHMWPE).

Q0907 Saghafi,N., Lam,D.K., Schmidt,B.L. Cannabinoids attenuate cancer pain and proliferation in a mouse model. Neuroscience Letters 2011; 488(-3-):247-251. >>> WIN-55,212-2; ACEA; AM1241; DMSO; water; SC; Mice (nude); 2002; 2 weeks; Animal info (Foxn1 nu, athymic, 4-5 wks old, 20-25 g); cancer (oral); behavioral testing (mechanical allodynia); 50% DMSO used; wound clips used; pain.

Q0781 Schulte,A., Guenther,H.S., Phillips,H.S., Kemming,D., Martens,T., Kharbanda,S., Soriano,R.H., Modrusan,Z., Zapf,S., Westphal,M., Lamszus,K. A Distinct Subset of Glioma Cell Lines with Stem Cell-like Properties Reflects the Transcriptional Phenotype of Glioblastomas and Overexpresses CXCR4 as Therapeutic Target. Glia 2011; 59(-4-):590-602. >>> AMD 3100; CSF/CNS (intratumoral); Mice (nude); 2004; ; Controls received mp w/ PBS; animal info (6-8 wks old, NMRI-nu/nu); ALZET brain infusion kit 2 used; cancer (glioma).

Q2239 Yamanaka,K., Nakahara,T., Yamauchi,T., Kita,A., Takeuchi,M., Kiyonaga,F., Kaneko,N., Sasamata,M. Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models. Clinical Cancer Research 2011; 17(-16-):5423-5431. >>> YM155; Mice (nude); 1003D; 1007D; 3, 7 days; Animal info (nu/nu); Model 1003D infused 3-days a week for 2 weeks; pumps replaced; cancer (malignant melanoma).

Q2252 Yamanaka,K., Nakata,M., Kaneko,N., Fushiki,H., Kita,A., Nakahara,T., Koutoku,H., Sasamata,M. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. INTERNATIONAL JOURNAL OF ONCOLOGY 2011; 39(-3-):569-575. >>> YM155; Saline, diluted; SC; Mice (nude); 1003D; 7 days; Controls received mp w/ vehicle; animal info (MRK nu-1, 5 wks old, female); cancer (breast).

Q0977 Blaya,B., Nicolau-Galmes,F., Jangi,S.M., Ortega-Martinez,I., onso-Tejerina,E., Burgos-Bretones,J., Perez-Yarza,G., Asumendi,A., Boyano,M.D. Histamine and Histamine Receptor Antagonists in Cancer Biology. Inflammation&Allergy Drug Targets 2010; 9(-3-):146-157. >>> Terfenadine; DMSO; PBS; SC; Mice (nude); ; Controls received mp w/ vehicle; animal info (C57BL/6, syngenic); cancer; Fig. 6, image of pump implanted in nude mice.

Q0582 Carcaboso,A.M., Elmeliegy,M.A., Shen,J., Juel,S.J., Zhang,Z.W.M., Calabrese,C., Tracey,L., Waters,C.M., Stewart,C.F. Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas. Cancer Research 2010; 70(-11-):4499-4508. >>> Topotecan; Water, sterile; SC; Mice (nude); 2001D; 8-12 hours; Animal info (CD1, nude); cancer (glioma).

Q1020 Cox,C.D., Garbaccio,R.M. Discovery of Allosteric Inhibitors of Kinesin Spindle Protein (KSP) for the Treatment of Taxane-Refractory Cancer: MK-0731 and Analogs. Anti-Cancer Agents in Medicinal Chemistry 2010; 10(-9-):697-712. >>> MK-0731; IV; Mice (nude); 24 hours; Animal info (naive); dose-response, Fig 12 ; half-life 4-10 hours (p. 710); MK-0731 is a KSP inhibitor (kinesin spindle protein); maximum tolerated dose (MTD) is 12 mg/kg.

Q00111 Demestre,M., Herzberg,J., Holtkamp,N., Hagel,C., Reuss,D., Friedrich,R.E., Kluwe,L., Von Deimling,A., Mautner,V.F., Kurtz,A. Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. Journal of Neuro-oncology 2010; 98(-1-):11-19. >>> Imatinib mesylate; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer (Plexiform neurofibromas); enzyme inhibitor (receptor tyrosine kinase); stress/adverse reaction: (see pg 13) “because of inflammation at the ALZET pump site, four mice of the treatment group had to be discontinued”; animal info (female, athymic nu/nu Balb/c); agent also known as Glivec or Gleevec; chemotherapeutic.

Q00129 Goda,M., Atagi,S., Amitani,K., Hobara,N., Kitamura,Y., Kawasaki,H. Nerve Growth Factor Suppresses Prostate Tumor Growth. JOURNAL OF PHARMACOLOGICAL SCIENCES 2010; 112(-4-):463-466. >>> Nerve growth factor; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ saline; cancer (prostate); animal info (BALB/c, Slc, 5 wks old, nu/nu).

Q0589 Iwasa,T., Okamoto,I., Takezawa,K., Yamanaka,K., Nakahara,T., Kita,A., Koutoku,H., Sasamata,M., Hatashita,E., Yamada,Y., Kuwata,K., Fukuoka,M., Nakagawa,K. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. British Journal of Cancer 2010; 103(-1-):36-42. >>> YM-155; cisplatin; carboplatin; DMSO; IV; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; animal info (male, nude, BALB/cAnNCrj-nu/nu, 5 weeks old); 0.1% DMSO used; cancer.

Q1143 Jani,J.P., Arcari,J., Bernardo,V., Bhattacharya,S.K., Briere,D., Cohen,B.D., Coleman,K., Christensen,J.G., Emerson,E.O., Jakowski,A., Hook,K., Los,G., Moyer,J.D., Pruimboom-Brees,I., Pustilnik,L., Rossi,A.M., Steyn,S.J., Su,C.Y., Tsaparikos,K., Wishka,D., Yoon,K., Jakubczak,J.L. PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy. MOLECULAR CANCER THERAPEUTICS 2010; 9(-4-):883-894. >>> PF-03814735; Cremophor EL; IP; Mice (nude; SCID); 1007D; 7 days; Controls received mp w/ vehicle; animal info (athymic, nude-Foxn1); cancer; enzyme inhibitor (Aurora kinase).

Q1168 Kioi,M., Vogel,H., Schultz,G., Hoffman,R.M., Harsh,G.R., Brown,J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. Journal of Clinical Investigation 2010; 120(-3-):694-705. >>> AMD 3100; Mice (nude); 21 days; Animal info (athymic, nu/nu); cancer; “An important feature of our data is that although we completed the drug infusion before the tumors were eradicated, the tumors continued to shrink and did not recur even long after the end of the infusion.” pg 702.

Q0402 Kozin,S.V., Kamoun,W.S., Huang,Y.H., Dawson,M.R., Jain,R.K., Duda,D.G. Recruitment of Myeloid but not Endothelial Precursor Cells Facilitates Tumor Regrowth after Local Irradiation. Cancer Research 2010; 70(-14-):5679-5685. >>> AMD 3100; IV; Mice (nude); 2 weeks; Animal info (mice athymic NCr/Sed nude (nu/nu) mice, female syngeneic FVB).

Q1180 Kraeber-Bodere,F., Bodet-Milin,C., Niaudet,C., Sai-Maurel,C., Moreau,A., Faivre-Chauvet,A., Thomare,P., Deleris,G., Estieu-Gionnet,K., Bikfalvi,A., Barbet,J., Paris,F. Comparative Toxicity and Efficacy of Combined Radioimmunotherapy and Antiangiogenic Therapy in Carcinoembryonic Antigen-Expressing Medullary Thyroid Cancer Xenograft. Journal of Nuclear Medicine 2010; 51(-4-):624-631. >>> CBO-p11; SC; Mice (nude); 2004; 25 days; Animal info (10 wks old); cancer; CBOP11 is a cyclopeptidic vascular endothelial growth inhibitor.

Q1194 Laursen,M.B., Pakula,M.M., Gao,S., Fluiter,K., Mook,O.R., Baas,F., Langklaer,N., Wengel,S.L., Wengel,J., Kjems,J., Bramsen,J.B. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Molecular BioSystems 2010; 6(-5-):862-870. >>> RNA, small interfering, unlocked nucleic acid modified; SC; Mice (nude); ; Animal info (NMRI, nu/nu, 8-10 wks old).

Q1201 Lenz,A., Sun,Y., Eichelbaum,E.J., Skelton,W.P., Pi,G., Vesely,D.L. Cardiac hormones eliminate some human squamous lung carcinomas in athymic mice. European Journal of Clinical Investigation 2010; 40(-3-):242-249. >>> Vessel dilator; kaliuretic peptide; atrial natriuretic factor; long-acting natriuretic peptide; Saline; SC; Mice (nude); 1007D; 28 days; Controls received mp w/ vehicle; animal info (male, athymic, nu/nu, 20 g); peptides; pumps replaced weekly; cancer (lung).

Q00340 Lin,E., Wang,Q.C., Swenson,S., Jadvar,H., Groshen,S., Ye,W., Markland,F.S., Pinski,J. The Disintegrin Contortrostatin in Combination With Docetaxel Is a Potent Inhibitor of Prostate Cancer In Vitro and In Vivo. PROSTATE 2010; 70(-12-):1359-1370. >>> Contortrostatin; SC; Mice (nude); 28 days; Controls received PBS IP; animal info (male, Nu/Nu, 5 wks old); cancer (prostate).

Q1189 Lo,A.S.Y., Ma,Q.Z., Liu,D.L., Junghans,R.P. Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor zeta Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors. Clinical Cancer Research 2010; 16(-10-):2769-2780. >>> Interleukin-2, recomb.; PBS; albumin, human; SC; Mice (nude); 7 days; Controls received mp w/ vehicle; animal info (8 wks old, female, Balb/C, nu/nu); cancer (melanoma); “These pumps are easily loaded and then placed s.c., minimizing discomfort and handling of the mice as needed for repeated IL2 administration by injection.” pg 2777.

Q1935 Malla,R., Gopinath,S., Alapati,K., Gondi,C.S., Gujrati,M., Dinh,D.H., Mohanam,S., Rao,J.S. Downregulation of uPAR and Cathepsin B Induces Apoptosis via Regulation of Bcl-2 and Bax and Inhibition of the PI3K/Akt Pathway in Gliomas. PLoS One 2010; 5(-10-):U120-U132. >>> Plasmid, MMP-9/cathepsin B; CSF/CNS; Mice (nude); ; Controls received mp w/ scrambled vector plasmid; cancer (glioma); pump infusion rate of 0.25 ul/hr.

Q0617 Martin,S.K., Diamond,P., Williams,S.A., To,L.B., Peet,D.J., Fujii,N., Gronthos,S., Harris,A.L., Zannettino,A.C.W. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica-The Hematology Journal 2010; 95(-5-):776-784. >>> T140; PBS; SC; Mice (nude); ; Postive controls received LP-1 cells stably over-expressing CXCL12; animal info (6 wks old, female, BALB/c); 100 ul sized pump used; T140 is a CXCR4 antagonist; bioluminescence.

Q00206 Masunaga,S., Tano,K., Nakamura,J., Watanabe,M., Kashino,G., Takahashi,A., Tanaka,H., Suzuki,M., Ohnishi,K., Kinashi,Y., Liu,Y., Ohnishi,T., Ono,K. Usefulness of Hexamethylenetetramine as an Adjuvant to Radiation and Cisplatin in the Treatment of Solid Tumors: its Independency of p53 Status. Journal of Radiation Research 2010; 51(-1-):27-35. >>> Uridine, bromodeoxy; hexamethylenetetramine; Saline, physiological; SC; Mice (nude); 2001D; 2001; 7 days; 24 hours; Cancer; toxicology; animal info (6-7 weeks old, female, syngenic, Balb/Ca).

P9990 Mercapide,J., Rappa,G., Anzanello,F., King,J., Fodstad,O., Lorico,A. Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. International Journal of Cancer 2010; 126(-5-):1206-1215. >>> Cyclophosphamide; CSF/CNS; Mice (nude); ; Controls received mp w/ sterile saline; animal info (6 wks old, female).

P9917 Murray,B.W., Guo,C.X., Piraino,J., Westwick,J.K., Zhang,C., Lamerdin,J., Dagostino,E., Knighton,D., Loi,C.M., Zager,M., Kraynov,E., Popoff,I., Christensen,J.G., Martinez,R., Kephart,S.E., Marakovits,J., Karlicek,S., Bergqvist,S., Smeal,T. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2010; 107(-20-):9446-9451. >>> PF-3758309; Mice (nude); 9 days; Dose response; enzyme inhibitor (P21-activated kinsase); animal info (athymic, CRL breed, 6-8 weeks); cancer; chemotherapeutic.

Q0795 Nalla,A.K., Asuthkar,S., Bhoopathi,P., Gujrati,M., Dinh,D.H., Rao,J.S. Suppression of uPAR Retards Radiation-Induced Invasion and Migration Mediated by Integrin beta-1/FAK Signaling in Medulloblastoma. PLoS One 2010; 5(-9-):U240-U255. >>> RNA, small interfering, uPAR; Mice (nude); 2001; 1 week; siRNA is within a plasmid vector (pU vector).

Q1312 Sapra,P., Wang,M.L., Bandaru,R., Zhao,H., Greenberger,L.M., Horak,I.D. Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide. NUCLEOSIDES NUCLEOTIDES&NUCLEIC ACIDS 2010; 29(-2-):97-112. >>> Oligonucleotide, antisense; SC; Mice (nude); 7 days; Controls received mp w/ EZN-3046, scrambled control nucleotide; animal info (4-5 wks old); antisense (EZN-3042); cancer (lymphoma).

Q00095 Schmidt,N.O., Ziu,M., Cargioli,T., Westphal,M., Giese,A., Black,P.M., Carroll,R.S. Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy. Translational Oncology 2010; 3(-1-):43-49. >>> Furegrelate; PBS; CSF/CNS (intratumoral); Mice (nude); 2004; 4 weeks; Controls received mp w/ vehicle; tissue perfusion (tumor); functionality of mp verified by residual volume; stress/adverse reaction: (see pg. 46) “hemosiderin deposits”; cancer (glioma); ALZET brain infusion kit used; animal info (Swiss, 4-6 wks old).

Q00341 Verpelli,C., Bertani,G., Cea,V., Patti,M., Bikfalvi,A., Bello,L., Sala,C. Anti-Angiogenic Therapy Induces Integrin-Linked Kinase 1 Up-Regulation in a Mouse Model of Glioblastoma. PLoS One 2010; 5(-10-):U70-U81. >>> PF4-DLR; RNA, small interfering; PBS; SC; CSF/CNS (intrathecal); Mice (nude); 2004; 10, 20 days; Controls received mp w/ vehicle; animal info (6 wks old, nude); peptides; ILK1-siRNA.

P9502 Armaiz-Pena,G.N., Mangala,L.S., Spannuth,W.A., Lin,Y.G., Jennings,N.B., Nick,A.M., Langley,R.R., Schmandt,R., Lutgendorf,S.K., Cole,S.W., Sood,A.K. Estrous Cycle Modulates Ovarian Carcinoma Growth. Clinical Cancer Research 2009; 15(-9-):2971-2978. >>> Estradiol, 17b-; progesterone; megestrol acetate; Cyclodextrin, b-; water; SC; Mice (nude); ; Replacement therapy (ovariectomy); animal info (female, athymic); cancer (ovarian).

Q0602 Beauparlant,P., Bedard,D., Bernier,C., Chan,H., Gilbert,K., Goulet,D., Gratton,M.O., Lavoie,M., Roulston,A., Turcotte,E., Watson,M. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anti-cancer Drugs 2009; 20(-5-):346-354. >>> GMX1777; NaCl; IV (jugular); Mice (nude; SCID); 2001D; 24 hours; Controls received mp w/ vehicle; animal info (BalbC nude, CB17, SCID/SCID, female); comparison of 72 h infusion pump vs 24 h mp; cancer (refractory solid tumors and lymphomas); “The 24 h infusion was the most effective administration schedule identified in mouse xenograft models” pg 352-353; cancer; chemotherapeutic.

P9597 Beauvais,D.M., Ell,B.J., McWhorter,A.R., Rapraeger,A.C. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. Journal of Experimental Medicine 2009; 206(-3-):691-705. >>> Synstatin (82-130); synstatin (94-119); synstatin (92-119); cyclic RGDfv; cyclic RADfv; PBS; DMSO; H2O, double distilled; Mice (nude); 2004; 4 weeks; Controls received mp w/vehicle, or PBS; cancer; peptides; animal info (6-8 wks old, female, athymic, BALB/c); 50% DMSO used; chemotherapeutic.

Q0580 Diamond,P., Labrinidis,A., Martin,S.K., Farrugia,A.N., Gronthos,S., To,L.B., Fujii,N., O’Loughlin,P.D., Evdokiou,A., Zannettino,A.C.W. Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss. Journal of Bone and Mineral Research 2009; 24(-7-):1150-1161. >>> T140; PBS; SC; Mice (nude); 1002; 28 days; Controls received mp w/ vehicle; animal info (4 wks old, female, Balb/c, nude); pumps replaced after 14 days; T140 (also known as 4F-Benzoyl-TE14011) is a CXCR4 inhibitor.

Q0586 Dilda,P.J., Decollogne,S., Weerakoon,L., Norris,M.D., Haber,M., Allen,J.D., Hogg,P.J. Optimization of the Antitumor Efficacy of a Synthetic Mitochondrial Toxin by Increasing the Residence Time in the Cytosol. Journal of Medicinal Chemistry 2009; 52(-20-):6209-6216. >>> Phenylarsonous acid; PBS; SC; Mice (nude); 1004; ; Controls received mp w/ vehicle; animal info (BalbC, nude, Female 7-9 week old); stability verified in vitro for at least 2 weeks at 4 or 37 degrees C; “There was a small accumulation of connective tissue at the delivery site of the osmotic pump in 7 of the 10 mice at the higher dose of PENAO. This is likely the result of a local inflammatory response triggered by the high concentrations of PENAO at the delivery site.” pg 6213; Phenylarsonous acid (PENAO) is a cysteine mimetic analogue of CAO; cancer.

P9606 Harada,H., Itasaka,S., Kizaka-Kondoh,S., Shibuya,K., Morinibu,A., Shinomiya,K., Hiraoka,M. The Akt/mTOR Pathway Assures the Synthesis of HIF-1-alpha Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry 2009; 284(-8-):5332-5342. >>> Luciferin, D-; glucose, 2-deoxy-D-; PBS; water; SC; Mice (nude); ; Controls received mp/vehicle; cancer; animal info (6 weeks old, male, BALB/c, nu/nu) IVIS-200; bioluminescence.

P9688 Harada,H., Itasaka,S., Zhu,Y., Zeng,L., Xie,X., Morinibu,A., Shinomiya,K., Hiraoka,M. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. British Journal of Cancer 2009; 100(-5-):747-757. >>> Luciferin, D-; PBS; SC; Mice (nude); 1007D; ; Animal info (BALB/c, nu/nu); IVIS-200; bioluminescence.

Q00045 Inbar-Rozensal,D., Castiel,A., Visochek,L., Castel,D., Dantzer,F., Izraeli,S., Cohen-Armon,M. A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. BREAST CANCER RESEARCH 2009; 11(-6-):U19-U29. >>> PJ-34; PBS; SC; Mice (nude); 14 days; controls received mp w/ vehicle or no treatment/no mp; enzyme inhibitor (poly-ADP-ribose polymerase); cancer (breast); no stress (R80); animal info (female, CD-1 nu/nu, 5-6 weeks old); “the 14-day treatment with a slow release of PJ-34 did not affect the vitality, growth, development, or any other behavior of the treated mice during the follow-up periods. (p. R80).

Q1136 Inoue,K., Aoi,N., Yamauchi,Y., Sato,T., Suga,H., Eto,H., Kato,H., Tabata,Y., Yoshimura,K. TGF-beta (2) is specifically expressed in human dermal papilla cells and modulates hair folliculogenesis. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 2009; 13(-11-12-):4643-4656. >>> SB431542; SC; Mice (nude); 4 weeks; Controls received mp w/ vehicle; animal info (6 wks old, Balb/c); enzyme inhibitor (kinase, TGF-beta type 1 receptor); rate of 0.25 ul/hr.

P9538 Kazi,A., Carie,A., Blaskovich,M.A., Bucher,C., Van,Thai, Moulder,S., Peng,H., Carrico,D., Pusateri,E., Pledger,W.J., Berndt,N., Hamilton,A., Sebti,S.M. Blockade of Protein Geranylgeranylation Inhibits Cdk2-Dependent p27Kip1 Phosphorylation on Thr187 and Accumulates p27Kip1 in the Nucleus: Implications for Breast Cancer Therapy. MOLECULAR AND CELLULAR BIOLOGY 2009; 29(-8-):2254-2263. >>> GGTI-2418; Polyethylene glycol; DMSO; SC; Mice (nude); 14 days; Controls received mp w/vehicle; cancer (breast); 20% DMSO used; enzyme inhibitor (geranylgeranyltransferase I); chemotherapeutic.

P9670 Lee,J.W., Shahzad,M.M.K., Lin,Y.G., rmaiz-Pena,G., Mangala,L.S., Han,H.D., Kim,H.S., Nam,E.J., Jennings,N.B., Halder,J., Nick,A.M., Stone,R.L., Lu,C.H., Lutgendorf,S.K., Cole,S.W., Lokshin,A.E., Sood,A.K. Surgical Stress Promotes Tumor Growth in Ovarian Carcinoma. Clinical Cancer Research 2009; 15(-8-):2695-2702. >>> Propranolol hydrochloride, S-; SC; Mice (nude); 2004; ; Controls received mp w/ PBS; no stress (see pg. 2697) “no significant complications”; cancer (ovarian); animal info (female, athymic, Ncr-nu).

P9629 Minematsu,T., Iwai,M., Sugimoto,K., Shirai,N., Nakahara,T., Usui,T., Kamimura,H. Carrier-Mediated Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9- dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small-Molecule Survivin Suppressant, into Human Solid Tumor and Lymphoma Cells. Drug Metabolism and Disposition 2009; 37(-3-):619-628. >>> YM155, 14C-; SC; Mice (nude); 1003D; 3 days; Cancer; animal info (5 wks old, male, Balb/c-nu/nu); “YM155 showed high distribution to tumor tissues after continuous administration to nude mice bearing PC-3 tumors.” pg 627.

P9582 Moroz,E., Carlin,S., Dyomina,K., Burke,S., Thaler,H.T., Blasberg,R., Serganova,I. Real-Time Imaging of HIF-1-alpha Stabilization and Degradation. PLoS One 2009; 4(-4-):U44-U56. >>> Luciferin, D-; SC; Mice (nude); 1007D; ; Animal info (6 wks old, Ncr nu/nu); IVIS Imaging.

P9897 Onimaru,M., Yonemitsu,Y., Fujii,T., Tanii,M., Nakano,T., Nakagawa,K., Kohno,R., Hasegawa,M., Nishikawa,S., Sueishi,K. VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B. American Journal of Physiology-Heart and Circulatory Physiology 2009; 297(-5-):H1685-H1696. >>> AFL-4; IP; Mice (nude); 1007D; 7 days; Controls received mp w/control antibody; animal info (male, C57BL/6J, 6 wks old, nu; BALB/C, nu, 5 wks old); AFL-4 is a murine VEGFR3-specific neutralizing antibody.

Q00238 Richards,A., McGeechan,K., Niknam,M., Salomon,R., Kurek,C., Dong,Q.H., Patel,M.I. Prolonging androgen sensitivity in prostate cancer – a role for COX inhibitors?. ANZ JOURNAL OF SURGERY 2009; 79(-9-):641-647. >>> Celecoxib; DMSO; ethanol; water; SC; Mice (nude); 2004; 8 weeks; Controls received mp w/ vehicle; long-term study; pumps replaced after 28 days; stress/adverse reaction (see pg. 646 “local skin dryness and erosion”); enzyme inhibitor (COX-2); cancer (prostate); incorrectly stated pump model 2400; 50% DMSO used; 15% ethanol used.

P9819 Savai,R., Langheinrich,A.C., Schermuly,R.T., Pullamsetti,S.S., Dumitrascu,R., Traupe,H., Rau,W.S., Seeger,W., Grimminger,F., Banat,A. Evaluation of Angiogenesis Using Micro-Computed Tomography in a Xenograft Mouse Model of Lung Cancer. NEOPLASIA 2009; 11(-1-):48-56. >>> Bevacizumab; IV (jugular); Mice (nude); 2002; 14 days; Controls received mp w/ distilled water; animal info (female, C57BL/6, 5-7 wks old, BALB/c, nu/nu, 7-8 wks old); pump implated IP; bevacizumab is a anti-VEGF antibody; “This delivery (using ALZET pumps) mimics local delivery of antivascular agents and can be used effectively alone or in combination with cytotoxic chemotherapy for site-specific drug delivery for lung cancer treatment. As expected, continuous infusion of bevacizumab decreased lung tumor volume and tumor perfusion, with an added survival advantage compared to the untreated group.” pg 55; cancer (lung); antibody.

P9478 Schauff,A.K., Kim,E.L., Leppert,J., Nadrowitz,R., Wuestenberg,R., Brockmann,M.A., Giese,A. Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation. Journal of Neuro-oncology 2009; 91(-3-):241-249. >>> Furegrelate; CSF/CNS (intratumoral); Mice (nude); 1002; 14 days; Controls were untreated; enzyme inhibitor (thromboxane synthase TXSA); cancer (glioma); tissue perfusion (tumor); ALZET brain infusion kit 3 used; animal info (NMRI).

P9708 Schmidt,N.O., Koeder,D., Messing,M., Mueller,F.J., Aboody,K.S., Kim,S.U., Black,P.M., Carroll,R.S., Westphal,M., Lamszus,K. Vascular endothelial growth factor-stimulated cerebral microvascular endothelial cells mediate the recruitment of neural stem cells to the neurovascular niche. Brain Research 2009; 1268(-;-):24-37. >>> Vascular endothelial growth factor, recomb. human; CSF/CNS (parenchyma); Mice (nude); 2004; ; Controls received mp w/PBS; animal info (6 wks old).

P9727 Skipper,J.B., McNally,L.R., Rosenthal,E.L., Wang,W.Q., Buchsbaum,D.J. In vivo Efficacy of Marimastat and Chemoradiation in Head and Neck Cancer Xenografts. ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES 2009; 71(-1-):1-5. >>> Marimastat; DMSO; SC; Mice (nude); 2002; 14 days; Controls received mp w/vehicle; cancer; animal info (3 mo old, female).

Q0812 Tsukioka,S., Uchida,J., Tsujimoto,H., Nakagawa,F., Sugimoto,Y., Oka,T., Kiniwa,M. Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: Evidence from a xenograft model of folate-depleted mice. Molecular Medicine Reports 2009; 2(-3-):393-398. >>> Fluorouracil, 5-; Sailne, sterile; SC; Mice (nude); 2002; 14 days; Animal info (BALB/cA-nu/nu, 4-5 wks old); cancer (colorectal); “oral S-1/LV therapy inhibited the growth of COL-1 tumors more effectively than the infusion of 5-FU/LV when administered at doses of similar toxicity” pg 397.

P9511 Uchibori,R., Okada,T., Ito,T., Urabe,M., Mizukami,H., Kume,A., Ozawa,K. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. JOURNAL OF GENE MEDICINE 2009; 11(-5-):373-381. >>> Ganciclovir; IP; Mice (nude); 28 days; Controls received mp w/ PBS; animal info (6 wks old, male, Balb/c, nu/nu); gene therapy.

P9364 Vanamala,S.K., Gopinath,S., Gondi,C.S., Rao,J.S. Effect of human umbilical cord blood cells on Ang-II-induced hypertrophy in mice. Biochemical and Biophysical Research Communications 2009; 386(-2-):386-391. >>> Angiotensin II; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; animal info (female, 8 wks old); dose (400 ng/kg/min).

Q0625 Yoon,H., Kim,D.J., Ahn,E.H., Gellert,G.C., Shay,J.W., Ahn,C.H., Lee,Y.B. Antitumor Activity of a Novel Antisense Oligonucleotide Against Akt1. Journal of Cellular Biochemistry 2009; 108(-4-):832-838. >>> Oligonucleotide, antisense; IP; Mice (nude); 1002; 14 days; Animal info (nu/nu); bioluminescence.

P9137 Barkan,D., Kleinman,H., Simmons,J.L., Asmussen,H., Kamaraju,A.K., Hoenorhoff,M.J., Liu,Z.Y., Costes,S.V., Cho,E.H., Lockett,S., Khanna,C., Chambers,A.F., Green,J.E. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Research 2008; 68(-15-):6241-6250. >>> ML-7; DMSO; Mice (nude); 2004; 1 week; Controls received mp w/ vehicle; enzyme inhibitor (myosin light chain kinase, MLCK); cancer (breast); animal info (4-6 wks old, female, BALB/c, nu/nu).

P9286 Ciceroni,C., Arcella,A., Mosillo,P., Battaglia,G., Mastrantoni,E., Oliva,M.A., Carpinelli,G., Santoro,F., Sale,P., Ricci-Vitiani,L., De Maria,R., Pallini,R., Giangaspero,F., Nicoletti,F., Melchiorri,D. Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells. Neuropharmacology 2008; 55(-4-):568-576. >>> LY379268; LY341495; SC; Mice (nude); 3 months; Controls received mp w/ saline; long-term study; pumps replaced every 15-28 days; cancer (brain, glioma); MRI; animal info (male, CD-1, nude); mGlu3 receptor-agonist, antagonist.

P8818 Conigliaro,A., Colletti,M., Cicchini,C., Guerra,M.T., Manfredini,R., Zini,R., Bordoni,V., Siepi,F., Leopizzi,M., Tripodi,M., Amicone,L. Isolation and characterization of a murine resident liver stem cell. CELL DEATH AND DIFFERENTIATION 2008; 15(-1-):123-133. >>> Fibroblast growth factor, bovine; Heparin; SC; Mice (nude); 10 days; Peptides.

P9210 Cox,C.D., Coleman,P.J., Breslin,M.J., Whitman,D.B., Garbaccio,R.M., Fraley,M.E., Buser,C.A., Walsh,E.S., Hamilton,K., Schaber,M.D., Lobell,R.B., Tao,W., Davide,J.P., Diehl,R.E., Abrams,M.T., South,V.J., Huber,H.E., Torrent,M., Prueksaritanont,T., Li,C., Slaughter,D.E., Mahan,E., Fernandez-Metzler,C., Yan,Y., Kuo,L.C., Kohl,N.E., Hartman,G.D. Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4- yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1- carboxamide (MK-0731) for the treatment of taxane-refractory cancer. Journal of Medicinal Chemistry 2008; 51(-14-):4239-4252. >>> MK-0731; piperidine analog, trans-fluoro-methylamine; Water; HCl; SC; Mice (nude); 2001D; 22 hours; Controls received mp w/ vehicle; dose-response (fig. 1); half-life (p.4246) 1 hour in rats; cancer (ovarian carcinoma); animal info (female, Crl: Nu/Nu-nuBR, 8-12 wks old, 25-30 g.); Kinesin spindle protein inhibitor; “subcutaneously implanted ALZET Osmotic Pumps were used for their ability to mimic a continuous iv infusion over the 22h course of the experiment… This protocol provides the best oppotunity to maintain plasma exposure for the required length of time without exposing the patient to high levels of drug following a bolus infusion.” (p. 4243).

P8846 Dikmen,Z.G., Gellert,G.C., Dogan,P., Yoon,H., Lee,Y.B., Ahn,C.H., Shay,J.W. In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. Journal of Cellular Biochemistry 2008; 104(-3-):985-994. >>> RX-0047; oligonucleotide, phosphorothioate antisense; SC; IP; Mice (nude); 1002; 14 days; Controls received no treatment; comparison of IP injections vs. mp; antisense (HIF-1a); cancer (lung, prostate); animal info (Nu/Nu).

P8817 Dings,R.P.M., Van Laar,E.S., Webber,J., Zhang,Y., Griffin,R.J., Waters,S.J., MacDonald,J.R., Mayo,K.H. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Letters 2008; 265(-2-):270-280. >>> Anginex; anginex topomimetic 0118; SC; Mice (nude); 28 days; Cancer (ovarian carcinoma); animal info (female, athymic nu/nu, 5-6 wks old); antiangiogenic.

P9170 Eichelbaum,E.J., Sun,Y., Alli,A.A., Gower,WR Jr, Vesely,D.L. Cardiac and kidney hormones cure up to 86% of human small-cell lung cancers in mice. European Journal of Clinical Investigation 2008; 38(-8-):562-570. >>> Atrial natriuretic factor; Saline; SC; Mice (nude); 1007D; 4 weeks; Controls received mp w/ vehicle; cancer (small cell lung); peptides; animal info (nu/nu, athymic); urodilatin is a kidney hormone; atrial natriuretic peptid, vessel dilator peptide, kaliuretic peptide, urodilation;.

P9285 Feldmann,G., Fendrich,V., McGovern,K., Bedja,D., Bisht,S., Alvarez,H., Koorstra,J.B.M., Habbe,N., Karikari,C., Mullendore,M., Gabrielson,K.L., Sharma,R., Matsui,W., Maitra,A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. MOLECULAR CANCER THERAPEUTICS 2008; 7(-9-):2725-2735. >>> IPI-269609; Cyclodextrin, 2-hydroxypropyl-b-; water, sterile; SC; Mice (nude); 2002; 6 weeks; 5, 7 days; Controls received mp w/ vehicle; comparison of daily PO vs. mp; pumps replaced every 2 wks; no stress (see pg. 2734); cancer (pancreatic); multiple pumps per animal (2); animal info (male, athymic CD1 nu/nu, 6-12 wks old); 30% cyclodextrin; Hedgehog inhibitor; “at the applied doses there were no signs of toxicity, weight loss, or other signs of adverse events in mice during the described treatment periods.” (p. 2734).

P9111 Gao,Y., Wu,X., Terauchi,M., Li,J.Y., Grassi,F., Galley,S., Yang,X., Weitzmann,M.N., Pacifici,R. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metabolism 2008; 8(-2-):132-145. >>> Parathyroid hormone (1-34), human; Mice (nude); 1002; 2 weeks; Controls received mp w/ vehicle; peptides; animal info (female, C57BL/6, 10 wks old, wt, nu/nu).

P8437 Henke,E., Perk,J., Vider,J., de Candia,P., Chin,Y., Solit,D.B., Ponomarev,V., Cartegni,L., Manova,K., Rosen,N., Benezra,R. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. NATURE BIOTECHNOLOGY 2008; 26(-1-):91-100. >>> Oligonucleotide, antisense, peptide conjugated; oligonucleotide, phosphorothioate antisense; peptide, F3; TBS; SC; Mice (nude); mice; 1007D; 1002; 14, 21 days; Controls received mp w/ vehicle or control peptide and oligo in non-conjugated form, or rcId1-PCAO; comparison of IV injections vs. mp; pumps replaced after 14 days; no stress (see pg. 95, 97); stability verified after 24 hours in 37 C, plasma up to 28 days in 37 C saline; antisense (Id1, rcId1); cancer (breast, lung carcinoma); peptides; toxicology; animal info (female, nude NCR; male, C57J/B6); antisense oligos covalently coupled to address peptide that targets tumor endothelial cells; “no adverse effects on treated mice have been observed.” (p. 97).

P9114 Iwasa,T., Okamoto,I., Suzuki,M., Nakahara,T., Yamanaka,K., Hatashita,E., Yamada,Y., Fukuoka,M., Ono,K., Nakagawa,K. Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines. Clinical Cancer Research 2008; 14(-20-):6496-6504. >>> YM155; Saline; Mice (nude); 1003D; 7 days; Controls received mp w/ vehicle; cancer (lung); animal info (BALB/c, athymic, 6 wks old, female); YM155 is a small inhibitor of survivin expression.

P8815 Jin,H.K., Yang,R.H., Zheng,Z., Romero,M., Ross,J., Bou-Reslan,H., Carano,R.A.D., Kasman,I., Mai,E., Young,J., Zha,J.P., Zhang,Z.M., Ross,S., Schwall,R., Colbern,G., Merchant,M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Research 2008; 68(-11-):4360-4368. >>> Hepatocyte growth factor, human; Dextran sulfate; IP; Mice (nude); 1002; ; Controls received mp w/ vehicle; functionality of mp verified by human HGF serum levels; pumps replaced every 12 to 14 days; cancer (pancreatic); peptides; animal info (female, nu/nu).

P9143 Kim,J.W., Choi,Y.L., Vallentin,A., Hunrichs,B.S., Hellerstein,M.K., Peehl,D.M., Mochly-Rosen,D. Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Research 2008; 68(-16-):6831-6839. >>> TAT (47-57); IIV5-3, beta-; Saline; Mice (nude); 2001; 5 weeks; Controls received mp w/ vehicle or TAT (47-57); pumps replaced every 2 weeks; half-life (p. 6832) ~ 2 wks; enzyme inhibitor (PKC betaII, protein kinase C); animal info (6 wks old, male).

P9680 Martens,T., Laabs,Y., Guenther,H.S., Kemming,D., Zhu,Z.P., Witte,L., Hagel,C., Westphal,M., Lamszus,K. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clinical Cancer Research 2008; 14(-17-):5447-5458. >>> Cetuximab; CSF/CNS (intratumoral); Mice (nude); 2004; ; Controls received mp w/ vehicle; tissue perfusion (tumor); cancer (glioblastoma); ALZET brain infusion kit 2 used; animal info (NMRI- nu/nu, 6-8 wks old); cetuximab is a monoclonal antibody against EGFR.

P9728 Mersereau,J.E., Levy,N., Staub,R.E., Baggett,S., Zogric,T., Chow,S., Ricke,W.A., Tagliaferri,M., Cohen,I., Bjeldanes,L.F., Leitman,D.C. Liquiritigenin is a plant-derived highly selective estrogen receptor-beta agonist. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2008; 283(-1-2-):49-57. >>> Liquiritigenin; estradiol; SC; Mice (nude); 1 month; Controls received mp w/vehicle; cancer (breast); implies using 2ML4 pump (2.5ul/h); Liquiritigenin is a ER-beta selective compound extracted from the root of G. uralensis.

P9278 Nasr,R., Guillemin,M.C., Ferhi,O., Soilihi,H., Peres,L., Berthier,C., Rousselot,P., Robledo-Sarmiento,M., Lallemand-Breitenbach,V., Gourmel,B., Vitoux,D., Pandolfi,P.P., Rochette-Egly,C., Zhu,J., The,H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nature Medicine 2008; 14(-12-):1333-1342. >>> Bortezomib; cyclic AMP; H89; SC; Mice (nude); mice (transgenic); 1, 3, 6, 7 days; Controls received no treatment; enzyme inhibitor (PKA); cancer (acute promyelocytic leukemia); animal info (nude, PLZF-RARA-RARA-PLZF; PML-RARA5873A Tg); Bortezomib is a proteasome inhibitor.

P9129 Rodriguez,R., Hansen,L.T., Phear,G., Scorah,J., Spang-Thomsen,M., Cox,A., Helleday,T., Meuth,M. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clinical Cancer Research 2008; 14(-17-):5476-5483. >>> Thymidine; Saline; SC; Mice (nude); 2001; ; Controls received vehicle IP; animal info (male, 6 wks old, athymic, nu/nu).

P8791 Song,P.F., Sekhon,H.S., Fu,X.W., Maier,M., Jia,Y.B., Duan,J., Proskosil,B.J., Gravett,C., Lindstrom,J., Mark,G.P., Saha,S., Spindel,E.R. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Research 2008; 68(-12-):4693-4700. >>> Darifenacin; DMSO; PBS; SC; Mice (nude); 2004; 4 weeks; Controls received mp w/ vehicle; cancer (lung carcinoma); animal info (male, nu/nu); 50% DMSO; M3 mAChR antagonist.

Q1491 Udugamasooriya,D.G., Dineen,S.P., Brekken,R.A., Kodadek,T. A Peptoid “Antibody Surrogate” That Antagonizes VEGF Receptor 2 Activity. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 2008; 130(–):5744-5752. >>> GU40C4; Saline; SC; Mice (nude); 1002; 21 days; Controls received mp w/ control peptoid, saline; animal info (6-8 wks old, athymic, nu/nu, female); cancer.

P9469 Yano,A., Tsutsumi,S., Soga,S., Lee,M.J., Trepel,J., Osada,H., Neckers,L. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2008; 105(-40-):15541-15546. >>> Reveromycin A; SC; Mice (nude); 2004; 2.5 weeks; Controls received mp IP DMSO injections 2x/week; cancer (prostate carcinoma); animal info (male, nu/nu, 6 wks old); osteoclast-specific apoptosis-inducer.

P9077 Ye,L., Lewis-Russell,J.M., Sanders,A.J., Kynaston,H., Jiang,W.G. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 2008; 26(-2-):190-197. >>> Hepatocyte growth factor, recomb. human; NK4, recomb. human; SC; Mice (nude); 2004; 4 weeks; Cancer (prostate); animal info (athymic, male, CD-1, 4-6 wks old).